Formulations of MANP and uses thereof
AssigneeE-Star Biotech, LLC
InventorsJesse Crowne, Elizabeth John, Mark C. Manning, Robert W. Payne
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for, and includes, pharmaceutical formulations comprising an MANP peptide, methods of preparing such formulations, and uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present disclosure further provides for, and includes, methods for increasing the stability by a peptide formulation and for reducing aggregation during production of a peptide formulation.
Claims39
A pharmaceutical composition, comprising about 2 mg/ml modified atrial natriuretic peptide (MANP), about 10 mM acetate, about 275 mM sucrose, and about 0.02% polysorbate 20, wherein the pH is 4.4-6.6.
A vial containing a formulation comprising about 2 mg/ml modified atrial natriuretic peptide (MANP), about 10 mM acetate, about 275 mM sucrose, and about 0.02% polysorbate 20, wherein the pH is 4.4-6.6.
A pre-filled syringe containing about 2 mg/ml modified atrial natriuretic peptide (MANP), about 10 mM acetate, about 275 mM sucrose, and about 0.02% polysorbate 20, wherein the pH is 4.4-6.6.
A method of treating hypertension in a patient in need thereof, comprising administering to said patient a composition comprising about 2 mg/ml modified atrial natriuretic peptide (MANP), about 10 mM acetate, about 275 mM sucrose, and about 0.02% polysorbate 20, wherein the pH is 4.4-6.6.
Dependencies are inferred from the claim text.